Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Towards Optimal Treatment for High Risk Prostate Cancer; Stereotactic Pelvic Radiotherapy with Focal Boost to the Primary Tumour

NCT06204341 is registered in ClinicalTrials.gov with Haaglanden Medical Centre as lead sponsor.

NCT NCT06204341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06204341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Towards Optimal Treatment for High Risk Prostate Cancer; Stereotactic Pelvic Radiotherapy with Focal Boost to the Primary Tumour
Lead sponsor
Haaglanden Medical Centre
Phase
Not applicable
Overall status
Recruiting
Start date
January 2, 2024
Completion date
December 18, 2032
Enrollment
207 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk prostate carcinoma